SHERIDAN, WYOMING – May 7, 2025 – Convatec, a global leader in medical technologies focused on chronic condition management, has received regulatory approval for ConvaNiox™, a first-of-its-kind nitric oxide-generating multimodal dressing technology. This innovative product aims to significantly improve outcomes for patients with diabetic foot ulcers (DFUs), offering a powerful solution to an underserved segment of the wound care market.
The full launch of ConvaNiox™ is set for 2026, with an initial rollout scheduled for later this year in key European markets. This new technology combines the potent antimicrobial and antibiofilm properties of nitric oxide to accelerate healing in chronic wounds, particularly DFUs. In clinical trials, ConvaNiox™ demonstrated remarkable results, healing DFUs 60% faster than standard treatments.
ConvaNiox™: Revolutionizing Diabetic Foot Ulcer Treatment
Diabetic foot ulcers are a critical concern in global healthcare, affecting approximately 40–60 million people worldwide. These wounds result in not only physical disability but also emotional distress and considerable healthcare costs. In the U.S. alone, DFUs cost between $9–13 billion annually. Worse yet, DFUs are responsible for 85% of diabetes-related amputations, with patients facing a 2.5 times higher five-year mortality risk compared to those without foot complications.
ConvaNiox™ was developed after Convatec acquired 30 Technology’s anti-infective nitric oxide technology in 2023. This novel dressing utilizes nitric oxide to tackle the complexities of wound healing, addressing common challenges such as biofilm formation, which significantly hampers the healing process. The technology is poised to transform the treatment landscape, offering both healthcare professionals and patients a reliable option for managing DFUs.
Proven Clinical Efficacy: A Game-Changer for Healthcare Providers
In randomized controlled trials, ConvaNiox™ has been shown to reduce wound area three times faster than traditional treatments, with 60% more DFUs healing within 12 weeks. The new dressing technology offers an advanced, multimodal solution that is complementary to Convatec's established portfolio of advanced wound care products.
David Shepherd, President & Chief Operating Officer of Advanced Wound Care at Convatec, highlighted the potential impact of ConvaNiox™: “Regulatory approval marks the beginning of what this new technology can bring to the treatment of chronic conditions. For many patients, even small setbacks can have devastating consequences. ConvaNiox™ offers healthcare professionals and patients renewed confidence, unlocking the healing potential of nitric oxide.”
Initial Market Launch and Global Expansion Plans
ConvaNiox™ will first become available in France, Germany, Italy, Poland, Spain, and the UK later this year as part of an initial market launch. The focus will be on secondary care settings and specialist clinics where healthcare professionals can help manage DFUs more effectively. Convatec plans to expand availability to additional markets in the near future, following the initial launch phase.
This new product will complement Convatec’s strong advanced wound care portfolio, offering a best-in-class, transformative solution that promises to improve patient outcomes and reduce the overall burden of chronic wounds. As the company scales ConvaNiox™, the technology will also be explored for use in other clinical indications, further enhancing its impact across the wound care sector.
A Breakthrough in the Fight Against Antimicrobial Resistance
Dr. Divakar Ramakrishnan, Chief Technology Officer and Head of Research & Development at Convatec, emphasized the broader implications of the new technology. “ConvaNiox™ is uniquely powered by nitric oxide technology and is designed to provide a natural antimicrobial and antibiofilm mode of action with compelling clinical outcomes. Antimicrobial resistance is one of the key challenges of our time, and we believe this nitric oxide platform has significant potential for application across a multitude of MedTech devices.”
Convatec’s commitment to advancing healthcare through innovation is underscored by its strong pipeline, marking an exciting chapter in the company’s growth and its ongoing contributions to the wound care sector.
The Path Forward: ConvaNiox™ and Beyond
With ConvaNiox™, Convatec is poised to redefine the standard of care for diabetic foot ulcers and beyond, offering transformative solutions that can improve the quality of life for patients worldwide. Healthcare professionals can expect to see significant benefits in terms of faster healing times, reduced complications, and improved patient outcomes.